Embecta Corp. is a pure-play diabetes care company. Embecta is based in FRANKLIN LAKES, N.J.
| Revenue (Most Recent Fiscal Year) | $1.08B |
| Net Income (Most Recent Fiscal Year) | $95.40M |
| PE Ratio (Current Year Earnings Estimate) | 2.95 |
| PE Ratio (Trailing 12 Months) | 2.66 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.30 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 1.35 |
| Pre-Tax Margin (Trailing 12 Months) | 12.27% |
| Net Margin (Trailing 12 Months) | 8.59% |
| Return on Equity (Trailing 12 Months) | -19.25% |
| Return on Assets (Trailing 12 Months) | 10.82% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.68 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.17 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 2.18 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-10.81 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.56 |
| Earnings per Share (Most Recent Fiscal Year) | $2.95 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.48 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Common Shares Outstanding | 56.66M |
| Free Float | 55.92M |
| Market Capitalization | $307.10M |
| Average Volume (Last 20 Days) | 1.69M |
| Beta (Past 60 Months) | 0.81 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 93.83% |
| Annual Dividend (Based on Last Quarter) | $0.04 |
| Dividend Yield (Based on Last Quarter) | 0.74% |